Dr. Diehl Discusses Brentuximab Vedotin – Video

Posted: Published on November 22nd, 2011

This post was added by Dr P. Richardson



Volker Diehl, MD, Professor of Medicine, Emeritus, University of Cologne, Germany, discusses the recently approved drug brentuximab vedotin (SGN-35), an antibody-drug conjugate that has been approved to treat anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. It is marketed as Adcetris by Seattle Genetics, Inc. Brentuximab vedotin builds on the CD30 tumor marker discovered 30 years ago in cell line L428

View post:
Dr. Diehl Discusses Brentuximab Vedotin - Video

Related Posts
This entry was posted in Cell Medicine. Bookmark the permalink.

Comments are closed.